SELLAS Life Sciences (SLS) Cash & Equivalents Growth (3y) (2013 - 2026)

SELLAS Life Sciences (SLS) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 SELLAS Life Sciences 1.89 Bn 1.78 Bn - 64.86%

Historic Data

Download Data
DateValue
Mar 31, 2026 64.86%
Dec 31, 2025 -81.99%
Sep 30, 2025 662.32%
Jun 30, 2025 532.45%
Mar 31, 2025 0.00%
Dec 31, 2024 417.84%
Sep 30, 2024 -7.16%
Jun 30, 2024 349.79%
Mar 31, 2024 0.00%
Dec 31, 2023 0.00%
Sep 30, 2023 -21.28%
Jun 30, 2023 -68.95%
Mar 31, 2023 52.45%
Dec 31, 2022 455.32%
Sep 30, 2022 -77.77%
Jun 30, 2022 -80.13%
Mar 31, 2022 0.00%
Dec 31, 2021 -4.27%
Sep 30, 2021 38.15%
Jun 30, 2021 -77.39%